Swine Patents (Class 800/17)
-
Publication number: 20130276156Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.Type: ApplicationFiled: September 13, 2012Publication date: October 17, 2013Applicant: Intrexon CorporationInventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, JR., Mohan Philip
-
Publication number: 20130276157Abstract: Novel mutations in cytochrome P450C17 (CYP17) and cytochrome b5 (CYB5) affecting 16-androstene steroid synthesis are disclosed. The novel mutations result in alterations in production of critical intermediaries in the synthesis of 16-androstene steroids. Altering the activity of these enzymes may be useful in enhancing reducing androstenone synthesis and reducing boar taint. The identification of these novel mutations also allows for the development of transgenic pigs bearing mutations in these enzymes or for genetic screening to identify pigs on the basis of their CYP17 and/or CYB5 genotype. Pigs having these mutations may be selected and bred to produce pigs that have a lower incidence of boar taint.Type: ApplicationFiled: March 8, 2013Publication date: October 17, 2013Inventor: E. James Squires
-
Patent number: 8546643Abstract: The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof, LDL gene or part thereof, LDL receptor gene, or transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of atherosclerosis; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from atherosclerosis are disclosed.Type: GrantFiled: March 6, 2008Date of Patent: October 1, 2013Assignee: Aarhus UniversitetInventors: Jacob Fog Bentzon, Charlotte Brandt Sørensen, Peter Michael Kragh, Jacob Giehm Mikkelsen, Erling Falk, Lars Axel Bolund, Thomas Juhl Corydon
-
Publication number: 20130254910Abstract: The instant invention relates to the use of 24-hydroxylated vitamin D compounds as therapeutics in mammalian bone fracture repair. In addition, the instant invention relates to novel 24-hydroxylated vitamin D compound receptors which can be employed in the development of compounds capable of facilitating fracture repair in animals. The instant invention also relates to nucleic acids encoding such receptors as well as vectors, host cells, transgenic animals comprising such nucleic acids and screening assays employing such receptors.Type: ApplicationFiled: May 30, 2013Publication date: September 26, 2013Applicant: Shriners Hospital For ChildrenInventor: Rene St-Arnaud
-
Publication number: 20130219533Abstract: In some aspects, the invention provides compositions and methods for inhibiting viral infection. In some aspects, the invention provides compositions and methods useful for identifying antiviral compounds.Type: ApplicationFiled: June 17, 2011Publication date: August 22, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Thijn R. Brummelkamp, Jan E. Carette
-
Publication number: 20130212723Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which the HTNCre was applied.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Applicant: MICE WITH HORNS, LLCInventor: Mice With Horns, LLC
-
Publication number: 20130212722Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.Type: ApplicationFiled: February 15, 2013Publication date: August 15, 2013Applicant: MICE WITH HORNS, LLCInventor: Mice With Horns, LLC
-
Publication number: 20130202569Abstract: The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein.Type: ApplicationFiled: May 17, 2012Publication date: August 8, 2013Inventor: David Lee Ayares
-
Publication number: 20130191931Abstract: Described herein is the generation of Fah+/? heterozygote pigs by homologous recombination and somatic cell nuclear transfer, and a method for producing Fah?/? homozygote pigs. The Fah-deficient pigs of the disclosure can be used for a variety of research and therapeutic purposes, such as for the expansion of human hepatocytes, and as large animal models of hereditary tyrosinemia type 1, cirrhosis and hepatocellular carcinoma.Type: ApplicationFiled: March 23, 2011Publication date: July 25, 2013Applicants: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Markus Grompe, Scott Nyberg, Joseph Lillegard, Raymond Hickey
-
Publication number: 20130131317Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.Type: ApplicationFiled: January 25, 2013Publication date: May 23, 2013Applicant: Merrimack Pharmaceuticals, Inc.Inventor: Merrimack Pharmaceuticals, Inc.
-
Patent number: 8435520Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.Type: GrantFiled: February 11, 2011Date of Patent: May 7, 2013Inventors: Hendrik J. Schuurman, Emanuele Luigi Maria Cozzi, Francoise Richard, Guy Taccard, David James Graham White, Peter John Friend, John Wallwork, Paolo Brenner
-
Publication number: 20130111614Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: ApplicationFiled: April 11, 2011Publication date: May 2, 2013Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Christopher G.A. McGregor, Guerard W. Byrne
-
Patent number: 8389794Abstract: The present invention relates to a modified pig as a model for studying Alzheimer's disease. The modified pig model displays one or more phenotypes associated with Alzheimer's disease. Disclosed is also a modified pig comprising a modified human and/or porcine APP gene, and/or PS1 gene, and/or a transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of Alzheimer's disease; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from Alzheimer's disease are disclosed.Type: GrantFiled: March 6, 2008Date of Patent: March 5, 2013Assignee: Aarhus UniversitetInventors: Arne Lund Jørgensen, Ida Elisabeth Holm, Anders Lade Nielsen, Marianne Gregers Johansen, Jannik Ejnar Jakobsen
-
Publication number: 20130039991Abstract: The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans.Type: ApplicationFiled: June 20, 2012Publication date: February 14, 2013Inventors: Ajit Varki, Anna Maria Hedlund, Dzung Nguyen
-
Publication number: 20130031648Abstract: The present relates to use of follistatin-like related gene (FLRG) to increase muscle mass in a subject. As such, methods of ameliorating the severity of a pathologic condition characterized, at least in part, by a decreased amount, development or metabolic activity of muscle are provided. In addition transgenic non-human mammals expressing FLRG and having increased muscle mass as compared to a corresponding mammal having a myostatin-null mutation or a decreased level of myostatin are provided.Type: ApplicationFiled: August 6, 2012Publication date: January 31, 2013Inventor: Se-Jin Lee
-
Publication number: 20130024961Abstract: The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.Type: ApplicationFiled: November 30, 2010Publication date: January 24, 2013Inventors: Christopher Burlak, A. Joseph Tector, III
-
Publication number: 20130024960Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.Type: ApplicationFiled: July 8, 2010Publication date: January 24, 2013Applicants: UCL BUSINESS PLC, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THROMBOSIS RESEARCH INSTITUTEInventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
-
Publication number: 20120331576Abstract: The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified hereinType: ApplicationFiled: December 10, 2010Publication date: December 27, 2012Applicants: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Abraham Brass, Stephen Elledge
-
Patent number: 8324449Abstract: The invention provides acellular tissue matrices made from collagen-containing tissues of animals genetically modified so as to be deficient in the galactose 1,3-galactose epitope and methods of making and using such acellular tissue matrices.Type: GrantFiled: September 16, 2010Date of Patent: December 4, 2012Assignee: LifeCell CorporationInventors: David J. McQuillan, Edward S. Griffey, Herbert Daniel Beniker, Hui Xu
-
Patent number: 8309791Abstract: Transgenic artiodactyls are described as well as methods of making and using such artiodactyls.Type: GrantFiled: July 16, 2009Date of Patent: November 13, 2012Assignee: Recombinectics, Inc.Inventors: Scott C. Fahrenkrug, Daniel F. Carlson, Aron M. Geurts
-
Publication number: 20120278910Abstract: The present invention relates to a method for producing a transgenic pig in which immune rejection response is inhibited, and in which human HO-1 genes and TNFR1-Fe fusion genes are simultaneously expressed. The present invention also relates to a transgenic pig for organ transplantation, which is produced by the method, and in which immune rejection response is inhibited. The present invention also relates to a somatic-cell-donating cell strain for producing the transgenic pig, and to a method for producing organs, from the transgenic pig, in which the immune rejection response is inhibited.Type: ApplicationFiled: December 21, 2010Publication date: November 1, 2012Applicant: HANWHA L&C CORPORATIONInventors: Curie Ahn, Byeong Chun Lee, Jong Ik Hwang, Jae Seok Yang, Goo Jang, Bum Rae Cho, Ok Jae Koo, Jung Taek Kang, Dae Kee Kwon
-
Publication number: 20120259093Abstract: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.Type: ApplicationFiled: April 13, 2012Publication date: October 11, 2012Applicant: Merrimack Pharmaceuticals, Inc.Inventors: Stace LINDSAY, Robert Mulroy, Daniel Semeniuk
-
Publication number: 20120255047Abstract: The present invention is a porcine animal, tissue, organ, cells and cell lines, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha1,3GT). These animals, tissues, organs and cells can be used in xenotransplantation and for other medical purposes.Type: ApplicationFiled: July 13, 2010Publication date: October 4, 2012Inventors: Carol J. Phelps, David L. Ayares
-
Publication number: 20120233713Abstract: The present invention relates to methods and systems for inducible ablation of neural cells, in particular non-proliferating cells, such as oligodendrocytes and Schwann cells. The methods and systems include an animal model that can be specifically induced to display phenotypic traits or characteristics of a demyelination condition. The methods and systems disclosed herein are useful for drug screening, by identifying compounds or agents that promote remyelination or reversal of phenotypic traits or characteristics of demyelination conditions.Type: ApplicationFiled: September 2, 2010Publication date: September 13, 2012Inventors: Brian Popko, Maria Traka
-
Publication number: 20120222143Abstract: Compositions and methods for use of TALENs to make genetically modified livestock are set forth. The methods may include reporters for selecting cells or embryos that have been modified by TALENs for use as progenitor cells to make founder animals.Type: ApplicationFiled: February 24, 2012Publication date: August 30, 2012Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
-
Publication number: 20120185954Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: November 4, 2011Publication date: July 19, 2012Applicant: INTREXON CorporationInventors: Subba Reddy PALLI, Mohan Basavaraju Kumar
-
Publication number: 20120167239Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: February 20, 2002Publication date: June 28, 2012Applicant: TUTOGEN MEDICAL GMBHInventors: Subba Reddy Palli, Marianna Z. Kapitskaya
-
Publication number: 20120159653Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with MD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study MD development and methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with MD.Type: ApplicationFiled: July 23, 2010Publication date: June 21, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Publication number: 20120159654Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences involved in ADME and toxicology. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence involved in ADME and toxicology and the nucleic acids encoding said zinc finger nucleases. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences involved in ADME and toxicology.Type: ApplicationFiled: July 23, 2010Publication date: June 21, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
-
Patent number: 8173861Abstract: The present invention discloses a non-human animal model for a hereditary autosomal dominant disease. The non-human animal model expresses at least one phenotype associated with the disease and is obtained by a genetic determinant. The invention also relates to sperm cells and embryos comprising the genetic determinant for an autosomal dominant disease. Furthermore, methods for producing the non-human animal model, sperm cell, and embryos are disclosed.Type: GrantFiled: April 30, 2007Date of Patent: May 8, 2012Assignee: Aarhus UniversitetInventors: Lone Bruhn Madsen, Christian Bendixen, Knud Larsen, Connie Jakobsen Juhl, Bo Thomsen
-
Publication number: 20120066781Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The invention further provides phytases which have increased gastric lability. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate.Type: ApplicationFiled: May 20, 2010Publication date: March 15, 2012Inventors: David P. Weiner, Arne I. Solbak, JR., Ryan McCann
-
Patent number: 8106251Abstract: The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices.Type: GrantFiled: March 17, 2005Date of Patent: January 31, 2012Assignee: Revivicor, Inc.Inventors: David Ayares, Paul Rohricht
-
Publication number: 20120023599Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding cytochrome P450 (CYP) proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. The invention also provides zinc finger nucleases that target chromosomal sequence encoding CYP proteins, as well as methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.Type: ApplicationFiled: July 23, 2010Publication date: January 26, 2012Applicant: SIGMA-ALDRICH CO.Inventors: Edward Weinstein, Xiaoxia Cui, Victoria Brown-Kennerly
-
Publication number: 20120017288Abstract: The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).Type: ApplicationFiled: March 17, 2011Publication date: January 19, 2012Inventors: Kristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler
-
Publication number: 20110283375Abstract: The invention provides, among other things, activatable prothrombin, compositions comprising prothrombin, transgenic organisms for making prothrombin, methods for making the transgenic organisms, methods for making prothrombin-comprising compositions and for further purifying prothrombin from the compositions. Illustrative embodiments of the invention particularly provide transgenic mammals that express an exogenous gene for prothrombin and excrete the prothrombin encoded by the gene into their milk. In a highly particular illustrative embodiment in this regard the invention provides transgenic female pigs that express prothrombin in their milk. In this regard, the invention relates particularly to female pigs having stably incorporated in their genomes a DNA comprising a region that encodes prothrombin operably linked to a mammary gland-specific promoter. Further in this regard the invention relates to the milk containing the prothrombin and to prothrombin-containing compositions derived from the milk.Type: ApplicationFiled: June 1, 2011Publication date: November 17, 2011Applicant: Bellweather FarmsInventor: William Hugold Velander
-
Publication number: 20110265192Abstract: A sensor system for detecting the activation of specific nuclear receptors in a tissue of an animal is provided. The nuclear receptor sensor system comprises a sensor component comprising a nuclear receptor or part thereof coupled to a DNA-binding domain, and a reporter component comprising a reporter gene. Transgenic animals, such as a transgenic pig is provided, which comprises the components of the nuclear receptor sensor system in its genome. Also methods of producing the transgenic animal is provided as well as use of the transgenic animal for evaluating the activity of a nuclear receptor in vivo.Type: ApplicationFiled: September 3, 2009Publication date: October 27, 2011Applicants: SYDDANSK UNIVERSITET, AARHUS UNIVERSITETInventors: Lars Axel Bolund, Karsten Kristiansen, Jacob Giehm Mikkelsen, Nicklas Heine Staunstrup
-
Patent number: 8034330Abstract: It has been discovered that there are at least two significant antigens present on the cells of animal species such as pigs that elicit an immune or inflammatory response immediately upon implantation into humans or contact with human serum. The first is an ?-galactosyl (Gal) epitope, for example, Gal?(1?3)Gal?(1?4)GlcNac (linear B type 2) or Gal? (1?3)Gal?(1?4)Glc (linear B type 6). The second is an N-glycolylneuraminic acid (NeuGc) structure. By eliminating these epitopes, preferably by genetically engineering the animal so that the epitope is either not produced or is greatly reduced, or by chemical or enzymatic treatment of the animal's cells to remove the epitopes, it is possible to produce organs, tissues and cells suitable for xenotransplantation into humans. Cells can be rendered even more compatible by genetically engineering the animal to express a human complement regulatory protein (inhibitor), such as CD59, on its cells, or to express an excess of a pig complement regulatory protein.Type: GrantFiled: November 20, 2006Date of Patent: October 11, 2011Assignee: RBC Biotechnology, Inc.Inventor: Alex Zhu
-
Publication number: 20110239314Abstract: The present invention relates to a porcine alpha-S1-casein gene, a porcine alpha-S1-casein gene promoter, an expression comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates the mammary gland-specific expression of the target protein. Accordingly, an animal transformed with the promoter secretes the target protein in milk at high concentration, and thus can be advantageously used for the production of useful proteins.Type: ApplicationFiled: June 29, 2009Publication date: September 29, 2011Inventors: Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn
-
Publication number: 20110239317Abstract: The present invention provides isolated polynucleotides encoding promyostatin polypeptides or a peptide portion thereof, polynucleotides complementary thereto, and oligonucleotides that can specifically hybridize to such polynucleotides. The present invention also provides an isolated polynucleotide encoding a mature myostatin peptide.Type: ApplicationFiled: January 26, 2011Publication date: September 29, 2011Inventors: Se-Jin Lee, Alexandra C. McPherron
-
Publication number: 20110231943Abstract: In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.Type: ApplicationFiled: April 6, 2011Publication date: September 22, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: JAMES M. ROBL, YOSHIMI KUROIWA, POOTHAPPILLAI KASINATHAN, ISAO ISHIDA, KAZUMA TOMIZUKA
-
Publication number: 20110209229Abstract: The present invention provides a porcine beta-casein gene, a porcine beta-casein gene promoter, an expression vector comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates mammary gland-specific expression of the target protein and therefore can be useful for high-concentration production of beneficial proteins in milk.Type: ApplicationFiled: December 31, 2008Publication date: August 25, 2011Inventors: Jin Hoi Kim, Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn
-
Publication number: 20110197290Abstract: Swine animal models comprising a genomic disruption of an endogenous gene chosen from the group consisting of a Low-Density Lipoprotein Receptor gene LDLR, Duchene's Muscular Dystrophy (DMD) gene, and hairless gene (HR). Methods of preparing transfected cells useful for making a transgenic animal comprising exposing a first group of cells to a transfection agent and reseeding the group with additional cells that have not been exposed to the agent. The transgenic animals are useful for medical and scientific animal models of human diseases and conditions, as well as sources for cells, tissues, and biomaterials.Type: ApplicationFiled: February 11, 2011Publication date: August 11, 2011Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
-
Publication number: 20110191875Abstract: The invention provides compositions and methods for producing androstenedione (4-androstenedione), of improved purity and for modulating its production, for example by deletion or inactivation of ksdA, cxgA, cxgB, cxgC, or cxgD. The invention also provides methods and compositions, including nucleic acids that encode enzymes, for producing 1,4-androstadiene-3,17-dione (ADD) and related pathway compounds, including 20-(hydroxymethyl)pregna-4-en-3-one and 20-(hydroxymethyl)pregna-1,4-dien-3-one. The compositions of the invention include nucleic acids, probes, vectors, cells, transgenic plants and seeds, transgenic animals, kits and arrays.Type: ApplicationFiled: November 13, 2008Publication date: August 4, 2011Applicant: Verenium CorporationInventors: David Nunn, Catherine Pujol, Kelly Chatman
-
Patent number: 7989675Abstract: The present invention provides transgenic, large non-human animal models of diseases and conditions, as well as methods of using such animal models in the identification and characterization of therapies for the diseases and conditions.Type: GrantFiled: March 5, 2008Date of Patent: August 2, 2011Assignees: University of Iowa Research Foundation, The Curators of the University of MissouriInventors: Michael J. Welsh, Christopher S. Rogers, Randall Prather, John Engelhardt, Ziying Yan
-
Patent number: 7956238Abstract: The present invention relates to a novel promoter and its use in driving expression of foreign genes in transgenic animals (especially pigs). Accordingly, the present invention provides a method for producing transgenic animals harboring heterologous genes regulated by the promoter of the present invention.Type: GrantFiled: May 23, 2006Date of Patent: June 7, 2011Assignee: National Taiwan University (An University of Taiwan, R.O.C.)Inventors: Teng-Kuei Winston Cheng, Shinn-Chih Wu, Chi-Chen Hsu, Yu-Sheng Lin, Chih-Jen Lin, Kuo-Joan Cheng, Jih-Tay Hsu
-
Publication number: 20110126297Abstract: The present invention relates to a transgenic animal, which comprises in its genome a recombinant polynucleotide encoding one or more reporter proteins and a monocyte chemotactic protein-1 (MCP-1) promoter, wherein the one or more reporter proteins are expressed under the control of the MCP-1 promoter. A method for monitoring endogenous expression of MCP-1 in vivo is also provided, which is useful for identifying a regulator of the expression of MCP-1 or an anti-inflammatory agent.Type: ApplicationFiled: November 25, 2009Publication date: May 26, 2011Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventor: KURT MING-CHAO LIN
-
Publication number: 20110093965Abstract: The invention provides novel polypeptides having phospholipase activity, including, e.g., phospholipase A, B, C and D activity, patatin activity, phosphatidic acid phosphatases (PAP) and/or lipid acyl hydrolase (LAH) activity, nucleic acids encoding them and antibodies that bind to them. Industrial methods, e.g., oil degumming, and products comprising use of these phospholipases are also provided.Type: ApplicationFiled: September 21, 2007Publication date: April 21, 2011Applicant: Verenium CorporationInventors: Eileen O'Donoghue, Nelson R. Barton
-
Publication number: 20110083201Abstract: The present invention is related to the discovery that serpina3n, a secreted protein, binds to and inhibits granzyme B activity. The invention thus provides cells that include a polynucleotide encoding a granzyme B inhibitory serpin, pharmaceutical compositions including a granzyme B inhibitory serpin or a polynucleotide encoding a granzyme B inhibitory serpin, methods for treating a patient in need of immunosuppression by administration of a granzyme B inhibitory serpin, and methods of transplanting cells (e.g., islet cells) expressing a granzyme B inhibitory serpin.Type: ApplicationFiled: September 7, 2010Publication date: April 7, 2011Inventors: Ray V. Rajotte, R. Chris Bleackley, Greg Korbutt, Sarah J. Lord, Simonetta Sipione, Katia Carmine-Simmen, Fabrizio Giuliani
-
Patent number: 7919673Abstract: The present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor. The present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the pathogenesis and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic ?-cell mass.Type: GrantFiled: January 4, 2009Date of Patent: April 5, 2011Assignees: Ludwig-Maximilians-Universitat, MWM Biomodels GmbHInventors: Eckhard Wolf, Simone Renner, Barbara Kessler, Rüdiger Wanke, Nadja Herbach, Alexander Pfeifer, Andreas Hofmann
-
Patent number: RE42704Abstract: Materials and methods for producing fibrinogen in transgenic non-human mammals are disclosed. DNA segments encoding A?, B? and ? chains of fibrinogen are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing fibrinogen expressed from the introduced DNA segments. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous fibrinogen polypeptide chains are also disclosed.Type: GrantFiled: January 15, 1999Date of Patent: September 13, 2011Assignee: Pharming Intellectual Property B.V.Inventors: Donna E. Prunkard, Donald C. Foster